Actively Recruiting
Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery
Led by Zhongshan Ophthalmic Center, Sun Yat-sen University · Updated on 2026-04-01
204
Participants Needed
3
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if Anrikefon works as well as nalbuphine to control postoperative pain in adults undergoing ophthalmic surgery under general anesthesia. It will also learn about the safety and recovery outcomes of using Anrikefon. The main questions it aims to answer are: * Does Anrikefon provide pain relief that is not inferior to nalbuphine after ophthalmic surgery? * Does Anrikefon cause fewer central side effects, such as sedation or dizziness, compared with nalbuphine? * Does Anrikefon help patients recover and get discharged faster after day-surgery procedures? Researchers will compare Anrikefon to nalbuphine to see if Anrikefon can offer effective and safer perioperative analgesia for ophthalmic day-surgery patients. Participants will: * Receive either an intravenous dose of Anrikefon or nalbuphine during surgery. * Be monitored for pain scores, side effects, and recovery parameters after surgery. * Complete follow-up assessments.
CONDITIONS
Official Title
Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Scheduled for ophthalmic surgery under general anesthesia
- Aged 18 to 70 years
- American Society of Anesthesiologists (ASA) physical status I to III
- Body mass index (BMI) between 18 and 30 kg/m8
- Provided written informed consent to participate in the trial
You will not qualify if you...
- History of cardiovascular or cerebrovascular events within the past 6 months, including unstable angina, ischemic myocardial infarction, or heart failure
- Current uncontrolled hypertension (greater than 180/110 mmHg), aneurysm, or severe cardiac arrhythmia
- Severe respiratory diseases such as pulmonary fibrosis, severe pulmonary abscess, cor pulmonale, or advanced chronic obstructive pulmonary disease (COPD)
- Significant neurological disorders like brain injury, seizures, or severe psychiatric illnesses
- Known allergy to kappa opioid receptor agonists or general anesthetic agents used in the study
- Current peptic ulcer disease, gastrointestinal bleeding, or hypersensitivity to NSAIDs such as flurbiprofen axetil or paracetamol
- Use of opioid or non-opioid analgesics with last dose within five half-life periods
- Continuous opioid use for more than 10 days within 3 months before screening
- Use of drugs with unknown half-life that may affect analgesic efficacy within 14 days before randomization
- History of major surgery within the past 3 months that may affect postoperative pain assessment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Zhongshan Ophthalmic Center, Sun Yat-Sen University
Guangzhou, Guangdong, China, 510060
Actively Recruiting
2
The Affiliated Hospital of Yunnan University
Kunming, Yunnan, China, 650000
Not Yet Recruiting
3
Eye & ENT Hospital of Fudan University
Shanghai, China, 200031
Not Yet Recruiting
Research Team
X
Xiaoliang Gan, PhD
CONTACT
Y
Yanling Zhu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here